MyCEI Login


Preventing Anal Cancer: Results from the ANCHOR Study


Published Date: 04/25/2022

Expiration Date: 03/22/2025

CE Credit: CME:1


Joel Palefsky,M.D., C.M., F.R.C.P.(C)

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He trained in medicine and Internal Medicine at McGill University in Montreal Canada and in Infectious Diseases at Stanford University. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the founder and director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study that showed that treatment of anal cancer precursor lesions prevents the development of anal cancer. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society. He is founder and director of the International Papillomavirus Society International HPV Awareness campaign.

Learning Objectives

  • Understand the rationale for and design of the ANCHOR Study.
  • Know the results of the ANCHOR Study.
  • Be able to discuss the implications of the ANCHOR Study.

Continuing Education Credit Information